SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 55, Issue 5, 2015, Pages e1-e29

  Lowe, Sandra A ^a,b   Bowyer, Lucy ^b   Lust, Karin ^c   McMahon, Lawrence P ^d   Morton, Mark ^e   North, Robyn A ^f   Paech, Michael ^g   Said, Joanne M ^h  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g KING EDWARD MEMORIAL HOSPITAL   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

guideline; hypertension; management; preeclampsia; pregnancy

Indexed keywords

ANESTHETIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; MAGNESIUM SULFATE; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATTENUATION; BLOOD PRESSURE MONITORING; CESAREAN SECTION; CHRONIC DISEASE; DELIVERY; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECLAMPSIA; FEMALE; FLUID BALANCE; FOLLOW UP; GENERAL ANESTHESIA; HEMATOLOGIC DISEASE; HUMAN; INTENSIVE CARE; INTRAUTERINE GROWTH RETARDATION; INVASIVE PROCEDURE; KIDNEY DISEASE; LIVER DISEASE; LUNG EDEMA; MATERNAL HYPERTENSION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEONATAL RESPIRATORY DISTRESS SYNDROME; NEUROLOGIC DISEASE; NEUROPROTECTION; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL CARE; PRESSOR RESPONSE; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REGIONAL ANESTHESIA; RESUSCITATION; RISK FACTOR; SEIZURE; SPHYGMOMANOMETER; SPHYGMOMANOMETRY; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS PREVENTION; VAGINAL DELIVERY; VENOUS THROMBOEMBOLISM; ADULT; BLOOD PRESSURE MEASUREMENT; DISEASE COURSE; EVIDENCE BASED MEDICINE; GESTATIONAL AGE; HYPERTENSION, PREGNANCY-INDUCED; PHYSIOLOGIC MONITORING; PRE-ECLAMPSIA; PREGNANCY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84930715142     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12399     Document Type: Article

References (276)

1. Seligman S,. Which blood pressure? Br J Obstet Gynaecol 1987; 94: 497-498.
2. Macgillivray I,. The Hypertensive Diseases of Pregnancy. London: WB Saunders; 1983: pp 174-190.
3. Stone P, Cook D, Hutton J, et al., Measurements of blood pressure, oedema and proteinuria in a pregnant population of New Zealand. Aust N Z J Obstet Gynaecol 1995; 35: 32-37.
4. North RA, Taylor RS, Schellenberg JC,. Evaluation of a definition of pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 767-773.
5. Levine RJ, Ewell MG, Hauth JC, et al., Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥15 mm Hg to a level <90 mm Hg in association with proteinuria? Am J Obstet Gynecol 2000; 183: 787-792.
6. Martin JN Jr, Thigpen BD, Moore RC, et al., Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105: 246-254.
7. Cantwell R, Clutton-Brock T, Cooper G, et al., Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl 1): 1-203.
8. Wagner SJ, Acquah LA, Lindell EP, et al., Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control. Mayo Clin Proc 2011; 86: 851-856.
9. Williams KP, Galerneau F, Wilson S,. Changes in cerebral perfusion pressure in puerperal women with preeclampsia. Obstet Gynecol 1998; 92: 1016-1019.
10. Anonymous. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
11. Magee LA, Helewa M, et al., Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertension 2014; 4: 105-145.
12. Tranquilli AL, Brown MA, Zeeman GG, et al., The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertension: an International Journal of Women's Cardiovascular Health 2013; 3: 44-47.
13. NICE. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. National Institute for Health and Clinical Excellence. 2012 (Clinical guideline 107).
14. Chancellor J, Thorp JM Jr,. Blood pressure measurement in pregnancy. BJOG 2008; 115: 1076-1077.
15. Poon LC, Kametas N, Strobl I, et al., Inter-arm blood pressure differences in pregnant women. BJOG 2008; 115: 1122-1130.
16. Shennan A, Gupta M, Halligan A, et al., Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996; 347: 139-142.
17. Pickering TG, Hall JE, Appel LJ, et al., Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161.
18. Reinders LW, Mos CN, Thornton C, et al., Time poor: rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertension Pregnancy 2006; 25: 81-91.
19. Brown MA, Robinson A, Bowyer L, et al., Ambulatory blood pressure monitoring in pregnancy: what is normal? Am J Obstet Gynecol 1998; 178: 836-842.
20. Gupta M, Shennan AH, Halligan A, et al., Accuracy of oscillometric blood pressure monitoring in pregnancy and pre-eclampsia. BJOG 1997; 104: 350-355.
21. Lo C, Taylor RS, Gamble G, et al., Use of automated home blood pressure monitoring in pregnancy: is it safe?[see comment]. Am J Obstet Gynecol 2002; 187: 1321-1328.
22. Chung Y, de Greeff A, Shennan A,. Validation and compliance of a home monitoring device in pregnancy: microlife WatchBP home. Hypertension Pregnancy 2009; 28: 348-359.
23. Reinders A, Cuckson AC, Lee JT, Shennan AH,. An accurate automated blood pressure device for use in pregnancy and pre-eclampsia: the Microlife 3BTO-A. BJOG 2005; 112: 915-920.
24. Brown MA, Roberts L, Davis G, Mangos G,. Can we use the Omron T9P automated blood pressure monitor in pregnancy? Hypertension Pregnancy 2011; 30: 188-193.
25. Nouwen E, Snijder M, van Montfrans G, Wolf H,. Validation of the Omron M7 and Microlife 3BTO-A blood pressure measuring devices in preeclampsia. Hypertension Pregnancy 2012; 31: 131-139.
26. Stergiou GS, Giovas PP, Gkinos CP, Tzamouranis DG,. Validation of the A&D UM-101 professional hybrid device for office blood pressure measurement according to the International Protocol. Blood Press Monit 2008; 13: 37-42.
27. NCGC and BHS. Clinical management of primary hypertension in adults. NICE Clinical Guideline 127. 2011.
28. Wilton A, De Greef A, Shennan A,. Rapid assessment of blood pressure in the obstetric day unit using Microlife MaM technology. Hypertension Pregnancy 2007; 26: 31-37.
29. Brown MA, Roberts LM, Mackenzie C, et al., A prospective randomized study of automated versus mercury blood pressure recordings in hypertensive pregnancy (PRAM Study). Hypertension Pregnancy 2011; 31: 107-119.
30. Head GA, McGrath BP, Mihailidou AS, et al., Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens 2012; 30: 253-266.
31. Bellomo G, Narducci PL, Rondoni F, et al., Prognostic value of 24-hour blood pressure in pregnancy. JAMA 1999; 282: 1447-1452.
32. Brown MA, Mangos G, Davis G, Homer C,. The natural history of white coat hypertension during pregnancy. BJOG 2005; 112: 601-606.
33. Brown MA, Davis GK, McHugh L,. The prevalence and clinical significance of nocturnal hypertension in pregnancy. J Hypertens 2001; 19: 1437-1444.
34. Magee LA, Ramsay G, von Dadelszen P,. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens Pregnancy 2008; 27: 95-101.
35. Bulletins-Obstetrics ACoP. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159-167.
36. Tranquilli AL, Dekker G, Magee L, et al., The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertension 2014; 4: 97-104.
37. von Dadelszen P, Menzies JM, Payne B, Magee LA, Group PS. Predicting adverse outcomes in women with severe pre-eclampsia. Semin Perinatol 2011; 33: 152-7.
38. Menzies J, Magee LA, Macnab YC, et al., Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertension Pregnancy 2007; 26: 447-462.
39. Maynard SE, Karumanchi SA,. Angiogenic factors and preeclampsia. Semin Nephrol 2011; 31: 33-46.
40. Lindheimer MD, Kanter D,. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115: 365-375.
41. Ritchie A, Brown MA,. Proteinuria in pregnancy: from bench to bedside. Fetal Matern Med Rev 2010; 21: 1-23.
42. Kuo VS, Koumantakis G, Gallery ED, et al., Proteinuria and its assessment in normal and hypertensive pregnancy. Am J Obstet Gynecol 1992; 167: 723-728.
43. Meyer NL, Mercer BM, Friedman SA, Sibai BM,. Urinary dipstick protein: a poor predictor of absent or severe proteinuria. Am J Obstet Gynecol 1994; 170: 137-141.
44. Waugh J, Bell SC, Kilby M, et al., Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies. Hypertension Pregnancy 2001; 20: 205-217.
45. Brown MA, Buddle ML,. Inadequacy of dipstick proteinuria in hypertensive pregnancy. Aust N Z J Obstet Gynaecol 1995; 35: 366-369.
46. Dwyer BK, Gorman M, Carroll IR, Druzin M,. Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy. J Perinatol 2008; 28: 461-467.
47. Phelan LK, Brown MA, Davis GK, Mangos G,. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. Hypertension Pregnancy 2004; 23: 135-142.
48. Cote AM, Brown MA, Lam E, et al., Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008; 336: 1003-1006.
49. Koopmans CM, van Pampus MG, Groen H, et al., Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur J Obstet Gynecol Reprod Biol 2009; 146: 8-14.
50. Lind T, Godfrey KA, Otun H, Philips PR,. Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol 1984; 91: 128-132.
51. Rodeghiero F, Stasi R, Gernsheimer T, et al., Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
52. Homer CS, Brown MA, Mangos G, Davis GK,. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens 2008; 26: 295-302.
53. Sharma SK, Philip J, Whitten CW, et al., Assessment of changes in coagulation in parturients with preeclampsia using thromboelastography. Anesthesiology 1999; 90: 385-390.
54. Haram K, Svendsen E, Abildgaard U,. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009; 9: 8.
55. Gofton EN, Capewell V, Natale R, Gratton RJ,. Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol 2001; 185: 798-803.
56. Buchbinder A, Sibai BM, Caritis S, et al., Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186: 66-71.
57. Saudan P, Brown MA, Buddle ML, Jones M,. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998; 105: 1177-1184.
58. Nelson-Piercy C, Preeclampsia: the women at risk. In:, Crichtley HMA, Poston L, Waker J, eds. Preeclampsia. London: RCOG Press, 2003; 342-353.
59. Chappell LC, Enye S, Seed P, et al., Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008; 51: 1002-1009.
60. Witlin AG, Saade GR, Mattar F, Sibai BM,. Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. Am J Obstet Gynecol 1999; 180: 1322-1329.
61. Martin JN Jr, May WL, Magann EF, et al., Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol 1999; 180: 1407-1414.
62. Benton SJ, Hu Y, Xie F, et al., Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011; 205: 469. e1-8.
63. Verlohren S, Stepan H, Dechend R,. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci 2012; 122: 43-52.
64. Chappell LC, Duckworth S, Seed PT, et al., Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128: 2121-2131.
65. Grodski S, Jung C, Kertes P, et al., Phaeochromocytoma in pregnancy. Intern Med J 2006; 36: 604-606.
66. Hudsmith JG, Thomas CE, Browne DA,. Undiagnosed phaeochromocytoma mimicking severe preeclampsia in a pregnant woman at term. Int J Obstet Anesth 2006; 15: 240-245.
67. Lee-Ann HT, Brown MA, Mangos GJ, Davis GK,. Transient gestational hypertension: Not always a benign event. Pregnancy Hypertension 2012; 2: 22-27.
68. Knudsen UB, Kronborg CS, von Dadelszen P, et al., A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension 2012; 2: 8-15.
69. Sibiude J, Guibourdenche J, Dionne MD, et al., Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS ONE 2012; 7: e50208.
70. Rana S, Powe CE, Salahuddin S, et al., Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919.
71. Hall DR, Odendaal HJ, Steyn DW, Grove D,. Expectant management of early onset, severe pre-eclampsia: maternal outcome. BJOG 2000; 107: 1252-1257.
72. Bombrys AE, Barton JR, Nowacki EA, et al., Expectant management of severe preeclampsia at <27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008; 199: 247.e1-6.
73. Bombrys AE, Barton JR, Habli M, Sibai BM,. Expectant management of severe preeclampsia at 27(0/7) to 33(6/7) weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Perinatol 2009; 26: 441-446.
74. Belghiti J, Kayem G, Tsatsaris V, et al., Benefits and risks of expectant management of severe preeclampsia at <26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol 2011; 205: 465.e1-6.
75. Budden A, Wilkinson L, Buksh MJ, McCowan L,. Pregnancy outcome in women presenting with pre-eclampsia at <25 weeks gestation. Aust N Z J Obstet Gynaecol 2006; 46: 407-412.
76. Gaugler-Senden IPM, Huijssoon AG, Visser W, et al., Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks' gestation. Audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol 2006; 128: 216-221.
77. Abdel-Hady E-S, Fawzy M, El-Negeri M, et al., Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings? Arch Gynecol Obstet 2010; 282: 23-27.
78. Doyle LW, Crowther CA, Middleton P, et al., Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; CD004661.
79. Magee LA, Yong PJ, Espinosa V, et al., Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertension Pregnancy 2009; 28: 312-347.
80. Hall DR, Odendaal HJ, Steyn DW,. Expectant management of severe pre-eclampsia in the mid-trimester. Eur J Obstet Gynecol Reprod Biol 2001; 96: 168-172.
81. Hall DR, Odendaal HJ, Kirsten GF, et al., Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG 2000; 107: 1258-1264.
82. Sibai BM, Mercer BM, Schiff E, Friedman SA,. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171: 818-822.
83. Ganzevoort W, Rep A, Bonsel GJ, et al.,. Dynamics and incidence patterns of maternal complications in early-onset hypertension of pregnancy. BJOG 2007; 114: 741-750.
84. Langenveld J, Ravelli ACJ, van Kaam AH, et al., Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol 2011; 205: 540.e1-7.
85. Habli M, Levine RJ, Qian C, Sibai B,. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol 2007; 197: 406.e1-7.
86. Koopmans CM, Bijlenga D, Groen H, et al., Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988.
87. van der Tuuk K, Koopmans CM, Groen H, et al., Impact of the HYPITAT trial on doctors' behaviour and prevalence of eclampsia in the Netherlands. BJOG 2011; 118: 1658-1660.
88. Vijgen SMC, Koopmans CM, Opmeer BC, et al., An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial). BJOG 2010; 117: 1577-1585.
89. Tajik P, van der Tuuk K, Koopmans CM, et al., Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial. BJOG 2012; 119: 1123-1130.
90. Bewley S, Shennan A,. HYPITAT and the fallacy of pregnancy interruption. Lancet 2010; 375: 119; author reply -20.
91. Moriarty T,. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial). BJOG 2011; 118: 763; author reply 4.
92. Bijlenga D, Boers KE, Birnie E, et al., Maternal health-related quality of life after induction of labor or expectant monitoring in pregnancy complicated by intrauterine growth retardation beyond 36 weeks. Qual Life Res 2011; 20: 1427-1436.
93. Gulmezoglu AMHG,. Bed rest in hospital for suspected impaired fetal growth Oxford: Cochrane Library; 1999 [cited 2013].
94. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ,. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007; CD002252.
95. Beardmore KS, Morris JM, Gallery ED,. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertension Pregnancy 2002; 21: 85-95.
96. Wallenburg H,. Hemodynamics in hypertensive pregnancy. In: Rubin PC, ed. Handbook of Hypertension. Elsevier Science Publishers 1988; 91-95.
97. Baggio MR, Martins WP, Calderon AC, et al., Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. Ultrasound Med Biol 2011; 37: 53-58.
98. Duley LMS, Jones L,. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013. DOI: 10.1002/14651858.CD001449.pub3
99. Cotton DB, Gonik B, Dorman KF,. Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulfate. Am J Obstet Gynecol 1984; 148: 162-165.
100. Magee LA, Cham C, Waterman EJ, et al., Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327: 955-960.
101. Hennessy A, Thornton CE, Makris A, et al., A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial. Aust N Z J Obstet Gynaecol 2007; 47: 279-285.
102. Walters BN, Redman CW,. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br J Obstet Gynaecol 1984; 91: 330-336.
103. Visser W, Wallenburg HC,. A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. J Hypertens 1995; 13: 791-795.
104. Scardo JA, Vermillion ST, Hogg BB, Newman RB,. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996; 175: 336-338; discussion 8-40.
105. Jacobsen AF, Skjeldestad FE, Sandset PM,. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008; 198: 233.e1-7.
106. Jacobsen AF, Skjeldestad FE, Sandset PM,. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-912.
107. Kane EV, Calderwood C, Dobbie R, et al., A population-based study of venous thrombosis in pregnancy in Scotland 1980-2005. Eur J Obstet Gynecol Reprod Biol 2013; 169: 223-229.
108. Won HS, Kim dY, Yang MS, et al., Pregnancy-induced hypertension, but not gestational diabetes mellitus, is a risk factor for venous thromboembolism in pregnancy. Korean Circ J 2011; 41: 23-27.
109. Sultan AA, Tata LJ, West J, et al., Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013; 121: 3953-3961.
110. McLintock C, Brighton T, Chunilal S, et al., Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Obstet Gynaecol 2012; 52: 3-13.
111. Bates SM, Greer IA, Middeldorp S, et al., VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e691S-e736S.
112. Royal College of Obstetrics and Gynaecology. Thrombosis and embolism during pregnancy and the puerperium, Reducing the Risk. 2015, Green top guideline 37a.
113. Gigante A, Barbano B, Sardo L, et al., Hypercoagulability and Nephrotic Syndrome. Curr Vasc Pharmacol 2014; 12: 512-517.
114. Pincus KJ, Hynicka LM,. Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother 2013; 47: 725-734.
115. James A,. Thromboembolism in pregnancy. Obstet Gynecol 2011; 118: 718-729.
116. Harrop-Griffiths W, Cook T, Gill H, et al., Regional anaesthesia and patients with abnormalities of coagulation. Anaesthesia 2013; 68: 966-972.
117. Ganzevoort W, Rep A, Bonsel GJ, et al., A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 2005; 112: 1358-1368.
118. Perel P, Roberts I,. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6: CD000567.
119. Anthony JSL,. Fluid management in preeclampsia. Obstet Med 2013; 6: 100-104.
120. Brown MA, Zammit VC, Lowe SA,. Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. Clin Sci (Lond) 1989; 77: 599-604.
121. Walters BN,. Preeclamptic angina-a pathognomonic symptom of preeclampsia. Hypertension Pregnancy 2011; 30: 117-124.
122. Weinstein L,. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982; 142: 159-167.
123. Abildgaard U, Heimdal K,. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013; 166: 117-123.
124. Matchaba P, Moodley J, Corticosteroids for HELLP syndrome in pregnancy. The Cochrane Database Syst Rev 2004; CD002076.
125. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T,. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010; CD008148.
126. Fonseca JE, Mendez F, Catano C, Arias F,. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193: 1591-1598.
127. Barrilleaux PS, Martin JN Jr, Klauser CK, et al., Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. Obstet Gynecol 2005; 105: 843-848.
128. Mould S, Paruk F, Moodley J,. High-dose dexamethasone in the treatment of HELLP syndrome. Int J Gynaecol Obstet 2006; 93: 140-141.
129. Thornton C, Dahlen H, Korda A, Hennessy A, The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008 2013 [cited 208 6]. 476.e1-5.
130. Douglas KA, Redman CW,. Eclampsia in the United Kingdom. BMJ 1994; 309: 1395-1400.
131. Knight M, Ukoss. Eclampsia in the United Kingdom 2005. BJOG 2007; 114: 1072-1078.
132. Anonymous. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial.[Erratum appears in Lancet 1995 Jul 22;346(8969):258]. Lancet 1995; 345: 1455-1463.
133. Altman D, Carroli G, Duley L, et al., Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-1890.
134. Bakker R, Steegers EAP, Hofman A, Jaddoe VWV,. blood pressure in different gestational trimesters, fetal growth, and the risk of adverse birth outcomes: the generation R study. Am J Epidemiol 2011; 174: 797-806.
135. Vreeburg SA, Jacobs DJ, Dekker GA, et al., Hypertension during pregnancy in South Australia, part 2: risk factors for adverse maternal and/or perinatal outcome-results of multivariable analysis. Aust N Z J Obstet Gynaecol 2004; 44: 410-418.
136. Ferrer RL, Sibai BM, Mulrow CD, et al., Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000; 96: 849-860.
137. McCowan LM, Buist RG, North RA, Gamble G,. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996; 103: 123-129.
138. Churchill D, Duley L, Thornton JG, Jones L,. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database Syst Rev 2013; 7: CD003106.
139. Sibai BM,. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102: 181-192.
140. Hepburn M, Rosenberg K,. An audit of the detection and management of small-for-gestational age babies. Br J Obstet Gynaecol 1986; 93: 212-216.
141. Alfirevic Z, Neilson JP,. Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis. Am J Obstet Gynecol 1995; 172: 1379-1387.
142. Gonzalez JM, Stamilio DM, Ural S, et al., Relationship between abnormal fetal testing and adverse perinatal outcomes in intrauterine growth restriction. Am J Obstet Gynecol 2007; 196: e48-e51.
143. Grivell RM, Alfirevic Z, Gyte GML, Devane D,. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev 2012; 12: CD007863.
144. Lalor JG, Fawole B, Alfirevic Z, Devane D,. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2008; 1: CD000038.
145. Phelan JP,. The nonstress test: a review of 3000 tests. Am J Obstet Gynecol 1981; 139: 7-10.
146. Boehm FH, Salyer S, Shah DM,. WK V. Improved outcome of twice weekly nonstress testing. Obstet Gynecol 1986; 67: 566-568.
147. Maning FA,. Fetal biophysical profile. Obstet Gynecol Clin North Am 1999; 26: 557-577.
148. Turnbull DA, Wilkinson C, Gerard K, et al., Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004; 363: 1104-1109.
149. Abramovici D, Friedman SA, Mercer BM, et al., Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: Does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999; 180: 221-225.
150. Roberts D, Dalziel SR,. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2007; 4: CD004454.
151. Brownfoot FC, Gagliardi DI, Bain E, et al., Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2013; 8: CD006764.
152. Stutchfield PR, Whitaker R, Gliddon AE, et al., Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013; 98: F195-F200.
153. Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section Research T. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331: 662.
154. Alexandros S, George M, Stefania P, Pa IJ,. Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database Syst Rev 2009; 4: CD006614.
155. Murphy KE, Hannah ME, Willan AR, et al., Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet 2008; 372: 2143-2151.
156. Crowther CA, McKinlay CJD, Middleton P, Harding JE,. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2011; 6: CD003935.
157. Stiles AD,. Prenatal corticosteroids-early gain, long-term questions. N Engl J Med 2007; 357: 1248-1250.
158. Crowther CA, Doyle LW, Haslam RR, et al., Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. N Engl J Med 2007; 357: 1179-1189.
159. Crowther CA, Haslam RR, Hiller JE, et al., Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006; 367: 1913-1919.
160. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. 2010;The University of Adelaide, 2010 (http://www.adelaide.edu.au/arch/MagnesiumSulphate2010.pdf).
161. Berks D, Steegers EA, Molas M, Visser W,. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114: 1307-1314.
162. Makkonen N, Harju M, Kirkinen P,. Postpartum recovery after severe pre-eclampsia and HELLP-syndrome. J Perinat Med 1996; 24: 641-649.
163. Hutcheon JA, Lisonkova S, Joseph KS,. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25: 391-403.
164. Roberts CL, Algert CS, Morris JM, et al., Hypertensive disorders in pregnancy: a population-based study. Med J Aust 2005; 182: 332-335.
165. Ahmad AS, Samuelsen SO,. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG 2012; 119: 1521-1528.
166. Sibai BM,. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-265.
167. Mancia G, Bombelli M, Facchetti R, et al., Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226-232.
168. Trudel X, Brisson C, Larocque B, Milot A,. Masked hypertension: different blood pressure measurement methodology and risk factors in a working population. J Hypertens 2009; 27: 1560-1567.
169. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010. 2008 [cited 2013]. Available from: http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf.
170. Caton AR, Bell EM, Druschel CM, et al., Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54: 63-70.
171. Nakhai-Pour HR, Rey E, Berard A,. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89: 147-154.
172. Tranquilli AL, Giannubilo SR,. Use and safety of calcium channel blockers in obstetrics. Curr Med Chem 2009; 16: 3330-3340.
173. Yakoob MY, Bateman BT, Ho E, et al., The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62: 375-381.
174. Li DK, Yang C, Andrade S, et al., Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343: d5931.
175. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al., Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-2451.
176. Gallery ED, Ross MR, Gyory AZ,. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. Br Med J 1985; 291: 563-566.
177. Butters L, Kennedy S, Rubin PC,. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301: 587-589.
178. Lip GY, Beevers M, Churchill D, et al., Effect of atenolol on birth weight. Am J Cardiol 1997; 79: 1436-1438.
179. Hutcheon JA, Lisonkova S, Magee LA, et al., Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG 2011; 118: 49-54.
180. Makris A, Thornton C, Hennessy A,. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol 2004; 190: 577-578.
181. Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC,. Postpartum management of hypertension. BMJ 2013; 346: f894.
182. Firoz T, Melnik T,. Postpartum evaluation and long term implications. Best Pract Res Clin Obstet Gynaecol 2011; 25: 549-561.
183. Hartikainen-Sorri AL, Heikkinen JE, Koivisto M,. Pharmacokinetics of clonidine during pregnancy and nursing. Obstet Gynecol 1987; 69: 598-600.
184. Walker JJ,. Pre-eclampsia. Lancet 2000; 356: 1260-1265.
185. Dennis AT,. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia 2012; 67: 1009-1020.
186. Dyer RA, Piercy JL, Reed AR,. The role of the anaesthetist in the management of the pre-eclamptic patient. Curr Opin Anaesthesiol 2007; 20: 168-174.
187. Mortl MS,. MC Key issues in assessing, managing and treating patients presenting with severe preeclampsia. Int J Obstet Anesth 2000; 9: 39-44.
188. Engelhardt T, MacLennan FM,. Fluid management in pre-eclampsia. Int J Obstet Anesth 1999; 8: 253-259.
189. Clutton-Brock T,. Maternal deaths from anaesthesia. An extract from Why Mothers Die 2000-2002, the Confidential Enquiries into Maternal Deaths in the United Kingdom: Chapter 17: Trends in intensive care. Br J Anaesth 2005; 94: 424-429.
190. Tihtonen K, Koobi T, Yli-Hankala A, et al., Maternal haemodynamics in pre-eclampsia compared with normal pregnancy during caesarean delivery. BJOG 2006; 113: 657-663.
191. Hofmeyr G, Cyna A, Middleton P,. Prophylactic intravenous preloading for regional analgesia in labour. Cochrane Database Syst Rev 2004; CD000175.
192. Morgan PJ, Halpern SH, Tarshis J,. The effects of an increase of central blood volume before spinal anesthesia for cesarean delivery: a qualitative systematic review. Anest Analg 2001; 92: 997-1005.
193. Berends N, Teunkens A, Vandermeersch E, Van de Velde M,. A randomized trial comparing low-dose combined spinal-epidural anesthesia and conventional epidural anesthesia for cesarean section in severe preeclampsia. Acta Anaesthesiol Belg 2005; 56: 155-162.
194. Riley ET,. Editorial I: Spinal anaesthesia for Caesarean delivery: keep the pressure up and don't spare the vasoconstrictors. Br J Anaesth 2004; 92: 459-461.
195. Ramos-Santos E, Devoe LD, Wakefield ML, et al., The effects of epidural anesthesia on the Doppler velocimetry of umbilical and uterine arteries in normal and hypertensive patients during active term labor. Obstet Gynecol 1991; 77: 20-26.
196. Giles WB, Lah FX, Trudinger BJ,. The effect of epidural anaesthesia for caesarean section on maternal uterine and fetal umbilical artery blood flow velocity waveforms. BJOG 1987; 94: 55-59.
197. Neilson J, Preeclampsia and eclampsia. The Confidential Enquiry into Maternal and Child Health (CEMACH) Saving mothers lives: Reviewing maternal deaths to make motherhood safer 2003-2005 London: CEMACH; 2007.
198. Munnur U, de Boisblanc B, Suresh MS,. Airway problems in pregnancy. Crit Care Med 2005; 33 (10 Suppl): S259-S268.
199. Russell R,. Failed intubation in obstetrics: a self-fulfilling prophecy? Int J Obstet Anesth 2007; 16: 1-3.
200. Wallace DH, Leveno KJ, Cunningham FG, et al., Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. Obstet Gynecol 1995; 86: 193-199.
201. Dyer RA, Els I, Farbas J, et al., Prospective, randomized trial comparing general with spinal anesthesia for cesarean delivery in preeclamptic patients with a nonreassuring fetal heart trace. Anesthesiology 2003; 99: 561-569; discussion 5A-6A.
202. Popham P, Buettner A, Mendola M,. Anaesthesia for emergency caesarean section, 2000-2004, at the Royal Women's Hospital, Melbourne. Anaesth Intensive Care 2007; 35: 74-79.
203. Allam J, Malhotra S, Hemingway C, Yentis SM,. Epidural lidocaine-bicarbonate-adrenaline vs levobupivacaine for emergency Caesarean section: a randomised controlled trial. Anaesthesia 2008; 63: 243-249.
204. Stephens LC, Bruessel T,. Systematic review of oxytocin dosing at caesarean section. Anaesth Intensive Care 2012; 40: 247-252.
205. O'Hare R, McAtamney D, Mirakhur RK, et al., Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. Br J Anaesth 1999; 82: 283-285.
206. Alanoglu Z, Ates Y, Yilmaz AA, Tuzuner F,. Is there an ideal approach for rapid-sequence induction in hypertensive patients? J Clin Anesth 2006; 18: 34-40.
207. Ashton WB, James MF, Janicki P, Uys PC,. Attenuation of the pressor response to tracheal intubation by magnesium sulphate with and without alfentanil in hypertensive proteinuric patients undergoing caesarean section. Br J Anaesth 1991; 67: 741-747.
208. Rout CC, Rocke DA,. Effects of alfentanil and fentanyl on induction of anaesthesia in patients with severe pregnancy-induced hypertension. Br J Anaesth 1990; 65: 468-474.
209. Ramanathan J, Sibai BM, Pillai R, Angel JJ,. Neuromuscular transmission studies in preeclamptic women receiving magnesium sulfate. Am J Obstet Gynecol 1988; 158: 40-46.
210. Liu PL, Gatt S, Gugino LD, et al., Esmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine. Can Anaesth Soc J 1986; 33: 556-562.
211. Visalyaputra S, Rodanant O, Somboonviboon W, et al., Spinal versus epidural anesthesia for cesarean delivery in severe preeclampsia: a prospective randomized, multicenter study. Anest Analg 2005; 101: 862-868, table of contents.
212. Aya AG, Vialles N, Tanoubi I, et al., Spinal anesthesia-induced hypotension: a risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery. Anest Analg 2005; 101: 869-875, table of contents.
213. Henke VG, Bateman BT, Leffert LR,. Focused review: spinal anesthesia in severe preeclampsia. Anest Analg 2013; 117: 686-693.
214. Young P, Johanson R,. Haemodynamic, invasive and echocardiographic monitoring in the hypertensive parturient. Best Pract Res Clin Obstet Gynaecol 2001; 15: 605-622.
215. Martin SR, Foley MR,. Intensive care in obstetrics: an evidence-based review. Am J Obstet Gynecol 2006; 195: 673-689.
216. Dennis AT,. Transthoracic echocardiography in obstetric anaesthesia and obstetric critical illness. Int J Obstet Anesth 2011; 20: 160-168.
217. Duckitt K, Harrington D,. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.
218. North RA, McCowan LM, Dekker GA, et al., Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342: d1875.
219. Milne F, Redman C, Walker J, et al., The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330: 576-580.
220. Rodger MA, Betancourt MT, Clark P, et al., The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7: e1000292.
221. Kupferminc MJ, Eldor A, Steinman N, et al., Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
222. American College of Obstetricians and Gynecologists Women's Health Care Physicians. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol 2013; 122: 706-717.
223. Sgolastra F, Petrucci A, Severino M, et al., Relationship between periodontitis and pre-eclampsia: a meta-analysis. PLoS ONE 2013; 19: e71387.
224. Cetin I, Huppertz B, Burton G, et al., Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011; 1 (Suppl 1(0)): S4-S16.
225. Romero R, Nien JK, Espinoza J, et al., A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
226. Hyde C, Thornton S,. Does screening for pre-eclampsia make sense? BJOG 2013; 120: 1168-1170.
227. Levine RJ, Lam C, Qian C, et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
228. Venkatesha S, Toporsian M, Lam C, et al., Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
229. Maynard SE, Min J-Y, Merchan J, et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 2003; 111: 649-658.
230. Schneuer FJ, Nassar N, Guilbert C, et al., First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy. Pregnancy Hypertension 2013; 3: 215-221.
231. Poon LCY, Kametas NA, Maiz N, et al., First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.
232. Myatt L, Clifton RG, Roberts JM, et al., Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013; 120: 1183-1191.
233. Myers JE, Kenny LC, McCowan LM, et al., Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013; 120: 1215-1223.
234. Kleinrouweler CE, Wiegerinck MMJ, Ris-Stalpers C, et al., Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-787.
235. Kane SC, Da Silva Costa F, Brennecke SP,. Recent developments in early pregnancy screening: are we getting closer to the Holy Grail. MJA 2014; 200: 140-141.
236. Brown MA, Mackenzie C, Dunsmuir W, et al., Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007; 114: 984-993.
237. McDonald SD, Best C, Lam K,. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. BJOG 2009; 116: 1578-1584.
238. Roberts JM, Catov JM,. Aspirin for pre-eclampsia: compelling data on benefit and risk. Lancet 2007; 369: 1765-1766.
239. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Group PC. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-8.
240. Bujold E, Roberge S, Lacasse Y, et al., Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
241. Roberge S, Giguere Y, Villa P, et al., Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012; 29: 551-556.
242. Duley L, Henderson-Smart DJ, Meher S, King JF,. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; CD004659.
243. Duley L, Pre-eclampsia, eclampsia, and hypertension. Clinical evidence. 2011;2011.
244. Belizan JM, Villar J, Repke J,. The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. Am J Obstet Gynecol 1988; 158: 898-902.
245. Carroli G, Merialdi M, Wojdyla D, et al., Effects of calcium supplementation on uteroplacental and fetoplacental blood flow in low-calcium-intake mothers: a randomized controlled trial. Am J Obstet Gynecol 2010; 202: 45.e1-9.
246. Hofmeyr GJMZ, Nikodem VC, Mangesi L, et al., Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial. Hypertension Pregnancy 2008; 27: 299-304.
247. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L,. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010; 8: CD001059.
248. de Vries JI, van Pampus MG, Hague WM, et al., Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10: 64-72.
249. Rey E, Garneau P, David M, et al., Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58-64.
250. Kupferminc MJ, Rimon E, Many A, et al., Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med 2011; 24: 1042-1045.
251. Martinelli I, Ruggenenti P, Cetin I, et al., Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119: 3269-3275.
252. Empson M, Lassere M, Craig J, Scott J,. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859.
253. Kaandorp S, Di NM, Goddijn M, Middeldorp S,. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009; DOI: 10.1002/14651858.CD004734.pub3
254. Villar J, Purwar M, Merialdi M, et al., World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009; 116: 780-788.
255. Poston L, Briley AL, Seed PT, et al., Vitamins in pre-eclampsia trial C. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367: 1145-1154.
256. Rumbold A, Duley L, Crowther CA, Haslam RR,. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2008; 1: CD004227.
257. Roberts JM, Myatt L, Spong CY, et al., Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-1291.
258. Rumbold AR, Crowther CA, Haslam RR, et al., Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354: 1796-806.
259. Conde-Agudelo A, Romero R, Kusanovic JP, Hassan SS,. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204: 503.e1-e12.
260. Laresgoiti-Servitje E, Gomez-Lopez N,. The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms. Biol Reprod 2012; 87: 36.
261. Costantine MM, Cleary K,. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121: 349-353.
262. http://www.controlled-trials.com/ISRCTN23410175.
263. Wen SW, Chen XK, Rodger M, et al., Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008; 198: 45 e1-7.
264. Brown MC, Best KE, Pearce MS, et al., Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013; 28: 1-19.
265. Bellamy L, Casas JP, Hingorani AD, Williams DJ,. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974.
266. McDonald SD, Malinowski A, Zhou Q, et al., Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-930.
267. Skjaerven R, Wilcox AJ, Klungsoyr K, et al., Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ 2012; 345: e7677.
268. Berks D, Hoedjes M, Raat H, et al., Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 2013; 120: 924-931.
269. Williams D,. Long-term complications of preeclampsia. Semin Nephrol 2011; 31: 111-122.
270. Brusse I, Duvekot J, Jongerling J, et al., Impaired maternal cognitive functioning after pregnancies complicated by severe pre-eclampsia: a pilot case-control study. Acta Obstet Gynecol Scand 2008; 87: 408-412.
271. Aukes AM, Wessel I, Dubois AM, et al., Self-reported cognitive functioning in formerly eclamptic women. Am J Obstet Gynecol 2007; 197: 365.e1-6.
272. Wiegman MJ, de Groot JC, Jansonius NM, et al., Long-term visual functioning after eclampsia. Obstet Gynecol 2012; 119: 959-966.
273. Davis EF, Lazdam M, Lewandowski AJ, et al., Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012; 129: e1552-e1561.
274. Robinson M, Mattes E, Oddy WH, et al., Hypertensive diseases of pregnancy and the development of behavioral problems in childhood and adolescence: the Western Australian Pregnancy Cohort Study. J Pediatr 2009; 154: 218-224.
275. Whitehouse AJ, Robinson M, Newnham JP, Pennell CE,. Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring? Paediatr Perinat Epidemiol 2012; 26: 101-108.
276. Menzies J, Magee LA, Li J, et al., Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007; 110: 121-127.